tclmeelmo

8 ms·

1.
by tclmeelmo 10y ago
Someone on Youtube had what I thought was a clever solution: a piece of trim (looked like shoe molding) to bridge the 1" step. Cheap, and they claimed 100% effective.
2.
by tclmeelmo 10y ago
IIRC, the HP-15C used LU decomposition in its matrix math routines.
3.
by tclmeelmo 10y ago
> It also is very sensitive to resistance, to the point that I actually had to construct ramps for my car to climb the 1-inch lip at the entrance to my garage, otherwise it would stop at that point and refuse to go further. The pictures
4.
by tclmeelmo 10y ago
It would also seem possible for a spouse or other alternate driver of the car to have disabled those safeguards.
5.
by tclmeelmo 10y ago
This feature has me wondering what the SAE standards for automatic transmissions have to say on the matter, if anything? I'm not familiar with them, nor do I have access, but I'm hoping someone here might be helpful on either aspe
6.
Fixin' to Innovate(bittersoutherner.com)
1 points by tclmeelmo 10y ago|0 comments
7.
by tclmeelmo 10y ago
I am under the impression that they were experienced in IT but inexperienced in biomedical investments.
8.
by tclmeelmo 10y ago
This is really interesting. Do you know of anyone using it in production?
9.
by tclmeelmo 10y ago
An interesting question for me is, what will be the effect on wellness startups doing things like Fitbit or Soylent? I have no idea.
10.
by tclmeelmo 10y ago
Experienced investors aren't going to invest much if the science isn't on a good foundation. Even if they would, that's a pretty expensive way to fund research: it's cheaper to fund it by grants or through revenue.
11.
by tclmeelmo 10y ago
I would predict that it depends on where the money is coming from. For VC firms that are experienced in the biomedical space, Theranos changes nothing because they were already suspicious of Theranos. For firms that are inexperienced in the
12.
by tclmeelmo 10y ago
This article (by way of the WSJ) claims that Walgreens skipped their standard DD in partnering with Theranos, and that the deal overall was atypically structured.
13.
by tclmeelmo 10y ago
I remember playing around with REBOL a long time ago and it seemed useful and practical, but for reasons long forgotten I never used it. Maybe licensing? RED does look cool and I hadn't heard of it before, thanks for the tip. Don'
14.
by tclmeelmo 10y ago
I only use it like you guessed (and what I think it's best/appropriate for): gluing things together, embedded scripting, and Tk on internal tools/gizmos and early prototypes. I wasn't clear earlier, sorry. To be perfect
15.
by tclmeelmo 10y ago
In terms of acceleration they're certainly impressive, but does any Tesla qualify as a supercar when other indices of performance are considered? They're pretty heavy for one, and while they wear it extremely well, a low CoG can
16.
by tclmeelmo 10y ago
Thanks and thanks. To further bloviate, Tcl is my not-so-secret weapon. I first used it when doing exploratory work with some embedded one-off instruments and it made an impression because those doohickies are still running strong to this
17.
by tclmeelmo 10y ago
I don't think there's any simple answer to your specific questions based on what you've provided so far. I'm going to word vomit a bunch of stuff that might, with some Google/Wikipedia searches, help give you a bet
18.
Quality Woes a Challenge for Tesla’s High-Volume Car(wsj.com)
3 points by tclmeelmo 10y ago|0 comments
19.
by tclmeelmo 10y ago
Fascinating! and mind-blowing to think about operations on that kind of scale. Thanks for taking the time to share that.
20.
by tclmeelmo 10y ago
I'm unclear on how Kuvée fits into the three-tier system [0]. Are they trying to supplement/replace the incumbent distributors, or are they in between the vineyards and distributors? [0] https://en.wikipedia.org/w
21.
by tclmeelmo 10y ago
I should have also said in the original comment that Little, beyond the website, looks genuinely neat and I'm looking forward to exploring it further. I just finished skimming through the paper you have linked on the site and liked it
22.
by tclmeelmo 10y ago
I really, really like that "Why?" explanation page; I feel like many projects could benefit from copying that idea. Frequently, the first thought I have when I see projects is, "okay, neat, but why does this exist?", and
23.
by tclmeelmo 10y ago
I would imagine that this is supposed to help support their argument for conversion, that Kyle was inclined to use Jeremy's IP contributions in part because Kyle was otherwise incapable of practically accomplishing the company's g
24.
by tclmeelmo 10y ago
https://news.ycombinator.com/item?id=8994651 Also interesting because it makes reference to the earliest prototype.
25.
by tclmeelmo 10y ago
> The only proof he is using to say he was a co-founder is a YC application. Which, according to Jeremy's complaint, claims that the application was submitted by Kyle and repeatedly described Jeremy as a co-founder and their equity
26.
by tclmeelmo 10y ago
Claim 27 of this response enumerates the (claimed) consideration.
27.
by tclmeelmo 10y ago
An investor who also has at the very least a strong personal motivation in proving that SV and YC are capable of creating value in "hard tech": http://blog.samaltman.com/hard-tech-is-back
28.
by tclmeelmo 10y ago
I think the damage is largely limited to the reputation of the Silicon Valley medical startup community. The biomedical community (which doesn't have much overlap with the pg definition of "startup") has been very skeptica
29.
by tclmeelmo 10y ago
I realize your comment was said in good-natured jest, but I've actually had to shoot (based on behavior) several rabid wild animals over the past decade that were an immediate threat to me.
30.
Google’s biotech venture hit by ethical concerns over deal with luxury clinic(statnews.com)
4 points by tclmeelmo 10y ago|0 comments

More ›